Editorials

Osteonecrosis of the Jaw and Rheumatoid Arthritis. Is It the Disease or the Drugs?  R. Landesberg, P. Taxel  749

Prevention of Rheumatoid Arthritis: The Very First Steps  A. Masetto, M-C. Beaulieu, G. Boire  752

The Real World of Gout  R. Conway  755

Jeopardizing Validity by Mismeasurement of Quality of Life  J. Richardson, N.A. Day  758

Review

Reaching the Threshold: A Multilayer Pathogenesis of Macrophage Activation Syndrome  R. Strippoli, I. Caiello, F. De Benedetti  761

Articles

Longterm Safety and Efficacy of Tocilizumab in Patients with RA: A Cumulative Analysis of Up to 4.6 Years of Exposure  M.C. Genovese, A. Rubbert-Roth, J.S. Smolen, et al  768


Safety of Abatacept Administered Intravenously in Treatment of RA: Integrated Analyses of up to 8 Years of Treatment from the Abatacept Clinical Trial Program  M.E. Weinblatt, L.W. Moreland, R. Westhovens, et al  787

Association of Polymorphisms Modulating LDL Cholesterol with Susceptibility, Severity, and Progression of RA  Y-J. Park, S-A. Yoo, S. Choi, et al  798


First-degree Relatives of Patients with RA Exhibit High Prevalence of Joint Symptoms  I. Smolik, D.B. Robinson, C.N. Bernstein, H.S. El-Gabalawy  818

HDL Profiling Changes in Patients with RA Treated with TNF Inhibitors: A Cohort Study  A. Jamnitski, J.H. Levels, I.A. van den Oever, M.T. Nurmohamed  825


Association of Gastroesophageal Factors and Worsening of Forced Vital Capacity in SSc  X.J. Zhang, A. Bonner, M. Hudson, the Scleroderma Research Group, M. Baron, J. Pope  850


Soluble Biomarkers Associated with Response to Treatment with TNF Inhibitors in PsA  V. Chandran, H. Shen, R.A. Pollock, et al  866

Efficacy and Tolerability of Probenecid as Urate-lowering Therapy in Gout; Clinical Experience in High-prevalence Population  K. Pui, P.J. Gow, N. Dalbeth  872

Expression of PPAR α, β, γ, and H- and L-Prostaglandin D Synthase During OA in the Spontaneous Hartley Guinea Pig and Experimental Dog Models  S-S. Nebbaki, F.E. El Mansouri, H. Afif, et al  877


Kynurenic Acid in Synovial Fluid and Serum of Patients with RA, SpA, and OA  J. Parada-Turska, W. Zgrajka, M. Majdan  903

Statin Use in Giant Cell Arteritis: A Retrospective Study  J. Schmidt, T.A. Kermani, F. Muratore, C.S. Crowson, E.L. Matteson, K.J. Warrington  910

Contents continued opposite inside back cover . . .
Antibiotics for Treatment of ReA: A Systematic Review and Metaanalysis  C.E. Barber, J. Kim, R.D. Inman, J.M. Esdaile, M.T. James

Pediatric

Childhood-onset Eosinophilic Granulomatosis with Polyangiitis (formerly Churg-Strauss Syndrome):
A Contemporary Single-center Cohort
S. Gendelman, A. Zeft, S.J. Spalding

Race, Ethnicity, and Disease Outcomes in JIA:
A Cross-sectional Analysis of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
S. Ringold, T. Beukelman, P.A. Nigrovic, Y. Kimura, for the Carra Registry Investigators

Etanercept Improves Lipid Profile and Oxidative Stress Measures in Patients with JIA

Images in Rheumatology

Infectious Tenosynovitis in a Patient with Dermatomyositis and Vasculitis
C. Canella, M. Pacheco, F. Costa, E. Marchiori

Canadian Rheumatology Association Meeting
Ottawa, Ontario, Canada
February 13–16, 2013
Abstracts

Letters

CCL18 Activates Fibroblast-like Synoviocytes in Patients with RA
A. Takayasu, Y. Miyabe, W. Yokoyama, et al.

Cyclophosphamide Exposure in Pediatric SLE Is Associated with Reduced Serum Anti-Müllerian Hormone Levels

Meetings in Rheumatology

www.jrheum.org